(Q37316037)

19 August 2017

1 reference

title

Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

Dina K Patel

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

28

1 reference

19 August 2017

issue

11 Pt 2

1 reference

19 August 2017

page(s)

31S-41S

1 reference

EGFR-targeted therapies in colorectal cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Epothilones in breast cancer: review of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

FDA drug approval summary: panitumumab (Vectibix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Panitumumab: in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Current role of antibody therapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Nail toxicity associated with epidermal growth factor receptor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Implications of EGFR PharmDx kit for cetuximab eligibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Responsiveness to cetuximab without mutations in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Ethics in oncology: consulting for the investment industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

The price tag on progress--chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.11-SUPP.31S

10.1592/PHCO.28.11-SUPP.31S

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference